Spread | 0.09 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 1 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 7.11 |
Open | 7.03 |
1-Year Change | 14.31% |
Day's Range | 6.67 - 7.04 |
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing novel treatments for skin diseases. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin, a widely recognized, naturally sourced agent to treat topical dermatological conditions, administered through single-use precision applicator. The Company is developing VP-102 for the treatment of molluscum contagiosum, or molluscum, a contagious and primarily pediatric viral skin disease, and common warts. It is conducting Phase II clinical trial for the treatment of plantar warts.
BRIEF: For the fiscal year ended 31 December 2021, Verrica Pharmaceuticals Inc revenues increased from $0K to $12M. Net loss decreased 18% to $35.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-Based Compensation in SG&A decrease of 50% to $4.5M (expense), Research and development - Balancing val decrease of 3% to $14.4M (expense).